Work

Subgroup outcomes from RAISE: A randomized, Phase 3 trial of zilucoplan in generalized myasthenia gravis (P1-5.006)

Year: 2023

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000202904

Authors: Michael D. Weiss, Saskia Bresch, Miriam Freimer, Channa Hewamadduma, Raul Juntas-Morales, M. Isabel Leite, Angelina Maniaol, Masayuki Masuda, Kumaraswamy Sivakumar, Malgorzata Zajda, Babak Boroojerdi, Petra W. Duda, Guillemette De La Borderie, James F. Howard

Institutions: University of Washington Medical Center, Centre Hospitalier Universitaire de Nice, The Ohio State University, University of Sheffield, Vall d'Hebron Hospital Universitari, University of Oxford, Oslo University Hospital, Tokyo Medical University, University of Arizona, Medical University of Warsaw, UCB Pharma (Germany), UCB Pharma (Belgium), University of North Carolina at Chapel Hill

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367304403

FWCI: 0.162

Cites:

Cited by: 1

Related to: 10